Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...
Travere Therapeutics stock rises on sNDA submission plans for FILSPARI
Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) rose 7% following the company's announcement of its intent to submit a ...
Travere therapeutics SVP Elizabeth Reed sells $188,240 in stock
Elizabeth E. Reed, Senior Vice President, General Counsel, and Corporate Secretary of Travere Therapeutics, Inc. (NASDAQ:TVTX), reported selling 8,000 shares of the company's common stock. The sale, ...
Yahoo Finance15d
MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority Tag
Merck MRK announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval of its oral HIF-2α inhibitor, Welireg (belzutifan), for a new indication. The sNDA is ...
Travere Therapeutics to submit sNDA for FILSPARI in FSGS
Travere Therapeutics (TVTX) announced the Company has completed its Type C meeting with the U.S. Food and Drug Administration and plans to ...